160 related articles for article (PubMed ID: 35660663)
21. Minimum inhibitory concentrations of azithromycin in clinical isolates of
Uwamino Y; Aoki W; Inose R; Kamoshita Y; Mikita K; Namkoong H; Nishimura T; Matsushita H; Hasegawa N
Microbiol Spectr; 2024 Jun; 12(6):e0021824. PubMed ID: 38687080
[TBL] [Abstract][Full Text] [Related]
22. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.
Fattorini L; Li B; Piersimoni C; Tortoli E; Xiao Y; Santoro C; Ricci ML; Orefici G
Antimicrob Agents Chemother; 1995 Mar; 39(3):680-5. PubMed ID: 7793873
[TBL] [Abstract][Full Text] [Related]
23. [Genetic research about Mycobacterium avium complex].
Ogawa K
Kekkaku; 2011 Feb; 86(2):61-8. PubMed ID: 21404652
[TBL] [Abstract][Full Text] [Related]
24. Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex.
Park B; Shim TS; Jo KW; Won EJ; Kim MN; Sung H
Tuberculosis (Edinb); 2023 Dec; 143():102427. PubMed ID: 37918057
[TBL] [Abstract][Full Text] [Related]
25. Differences in Drug-Susceptibility Patterns between
Fernandez-Pittol M; Batista-Arnau S; Román A; San Nicolás L; Oliver L; González-Moreno O; Martínez JA; Amaro-Rodríguez R; Soler N; Gené A; González-Cuevas A; Tudó G; Gonzalez-Martin J
Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671265
[No Abstract] [Full Text] [Related]
26. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.
Schön T; Chryssanthou E
Int J Infect Dis; 2017 Feb; 55():122-124. PubMed ID: 28069470
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
Brown-Elliott BA; Iakhiaeva E; Griffith DE; Woods GL; Stout JE; Wolfe CR; Turenne CY; Wallace RJ
J Clin Microbiol; 2013 Oct; 51(10):3389-94. PubMed ID: 23946523
[TBL] [Abstract][Full Text] [Related]
28. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Talbot JA; Chomyc S; Davison E; Singer J; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG
Clin Infect Dis; 1998 Dec; 27(6):1401-5. PubMed ID: 9868650
[TBL] [Abstract][Full Text] [Related]
29. Genetic research about Mycobacterium avium complex.
Ogawa K
Kekkaku; 2013 Jan; 88(1):17-22. PubMed ID: 23513564
[TBL] [Abstract][Full Text] [Related]
30. Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against Mycobacterium intracellulare.
Zhang Z; Lu J; Du Y; Xie F; Wang Y; Sun B; Pang Y
J Glob Antimicrob Resist; 2019 Sep; 18():183-186. PubMed ID: 30953831
[TBL] [Abstract][Full Text] [Related]
31. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL
Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719
[TBL] [Abstract][Full Text] [Related]
33. Impact of different subspecies on disease progression in initially untreated patients with Mycobacterium avium complex lung disease.
Pan SW; Shu CC; Feng JY; Chien JY; Wang JY; Chan YJ; Yu CJ; Su WJ
Clin Microbiol Infect; 2021 Mar; 27(3):467.e9-467.e14. PubMed ID: 32360207
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and JustOne strips.
Babady NE; Hall L; Abbenyi AT; Eisberner JJ; Brown-Elliott BA; Pratt CJ; McGlasson MC; Beierle KD; Wohlfiel SL; Deml SM; Wallace RJ; Wengenack NL
J Clin Microbiol; 2010 May; 48(5):1749-52. PubMed ID: 20335412
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022.
Calado Nogueira de Moura V; Nguyen MH; Hunkins JJ; Daley CL; Khare R
J Antimicrob Chemother; 2023 Dec; 78(12):2849-2858. PubMed ID: 37864515
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.
Wang DM; Liu H; Zheng YL; Xu YH; Liao Y
Front Cell Infect Microbiol; 2023; 13():1282902. PubMed ID: 38029240
[TBL] [Abstract][Full Text] [Related]
37. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
38. Accurate subspecies-level identification of clinically significant Mycobacterium avium and Mycobacterium intracellulare by whole-genome sequencing.
Chawla R; Shaw B; von Bredow B; Chong C; Garner OB; Zangwill KM; Yang S
J Microbiol Methods; 2023 May; 208():106726. PubMed ID: 37120137
[TBL] [Abstract][Full Text] [Related]
39. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran.
Daneshfar S; Khosravi AD; Hashemzadeh M
PLoS One; 2022; 17(8):e0267320. PubMed ID: 35960778
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and treatment outcomes of Mycobacterium chimaera lung disease and antimicrobial susceptibility of the mycobacterial isolates.
Chen LC; Huang HN; Yu CJ; Chien JY; Hsueh PR
J Infect; 2020 Apr; 80(4):437-443. PubMed ID: 31954743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
